BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 27418820)

  • 1. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
    Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group.
    Salat D; Popov D; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S22-8. PubMed ID: 10919682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of long-term treatment with HFA albuterol.
    Ramsdell JW; Klinger NM; Ekholm BP; Colice GL
    Chest; 1999 Apr; 115(4):945-51. PubMed ID: 10208190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
    Ayres JG; Millar AB; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility.
    Pascoe S; Wu W; Zhu CQ; Singh D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2035-40. PubMed ID: 27621609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial.
    Escribano A; Tutuncu A; Löhr I; Carlholm M; Polanowski T
    Curr Med Res Opin; 2006 Jun; 22(6):1085-92. PubMed ID: 16846541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group.
    Baumgarten CR; Dorow P; Weber HH; Gebhardt R; Kettner J; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S17-21. PubMed ID: 10919681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler.
    Donnell D; Harrison LI; Ward S; Klinger NM; Ekholm BP; Cooper KM; Porietis I; McEwen J
    Eur J Clin Pharmacol; 1995; 48(6):473-7. PubMed ID: 8582466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
    Donohue JF; Wise R; Busse WW; Garfinkel S; Zubek VB; Ghafouri M; Manuel RC; Schlenker-Herceg R; Bleecker ER
    BMC Pulm Med; 2016 Apr; 16(1):65. PubMed ID: 27130202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
    Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A
    Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
    Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
    Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
    Perruchoud AP; Lundback B; Yigla M; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
    Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE
    Drugs; 2009; 69(5):549-65. PubMed ID: 19368417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
    Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM
    Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence.
    Singh D; Tutuncu A; Lohr I; Carlholm M; Polanowski T
    Int J Clin Pharmacol Ther; 2007 Sep; 45(9):485-95. PubMed ID: 17907591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma.
    Maesen FP; Greefhorst LP; Smeets JJ; Wald FD; Cornelissen PJ
    Respiration; 1997; 64(4):273-80. PubMed ID: 9257362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.